← Back to Search

Probiotic

Probiotic R-3750 for Ulcerative Colitis

Phase 1
Recruiting
Research Sponsored by Rise Therapeutics LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18-65 years of age
Ability to provide written informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial tests the safety and effect of an oral probiotic (R-3750) on mild to moderate ulcerative colitis patients, through patient-reported and physician-scored measures, blood, and fecal results.

Who is the study for?
Adults aged 18-65 with mild to moderate ulcerative colitis can join this trial. They must use birth control, avoid vaccinations during the study, and be able to consent. Those with recent drug abuse, probiotic use, chronic infections including COVID-19, major autoimmune diseases besides UC, high-dose steroid treatment for UC, severe allergies to probiotics or a history of stroke are excluded.
What is being tested?
The trial is testing the safety and effects of R-3750—a probiotic taken orally—on patients with ulcerative colitis. Participants will report their symptoms and undergo blood and stool tests to measure inflammation and how R-3750 affects fecal levels.
What are the potential side effects?
While specific side effects aren't listed for R-3750 in this summary, common side effects of probiotics may include digestive discomfort such as gas or bloating. Any unexpected reactions will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.
Select...
I agree to use effective birth control during and 30 days after the study.
Select...
I will not get any vaccines during the study, including flu or COVID shots.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To assess the tolerability of R-3750
Secondary study objectives
Clinical Response based on Inflammatory Bowel Disease Questionnaire (IBDQ) Scores

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

Rise Therapeutics LLCLead Sponsor
4 Previous Clinical Trials
144 Total Patients Enrolled
Mayo ClinicOTHER
3,349 Previous Clinical Trials
3,061,060 Total Patients Enrolled
11 Trials studying Ulcerative Colitis
525 Patients Enrolled for Ulcerative Colitis
University of Colorado, DenverOTHER
1,808 Previous Clinical Trials
2,822,204 Total Patients Enrolled
1 Trials studying Ulcerative Colitis
36 Patients Enrolled for Ulcerative Colitis

Media Library

R-3750 (Probiotic) Clinical Trial Eligibility Overview. Trial Name: NCT05666960 — Phase 1
Ulcerative Colitis Research Study Groups:
Ulcerative Colitis Clinical Trial 2023: R-3750 Highlights & Side Effects. Trial Name: NCT05666960 — Phase 1
R-3750 (Probiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05666960 — Phase 1
~11 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top